Inimmune Corporation announces First Subject Dosed in First-in-Human Phase 1 Clinical Trial of its novel intranasal TLR4 agonist, INI-2004, for the Treatment of Allergic Rhinitis and FDA Clearance of IND application for INI-2004
Milestone marks transition of Inimmune Corporation to a clinical-stage company MISSOULA, Mont., Aug. 2, 2023 /PRNewswire/ — Inimmune Corporation (“Inimmune”), a clinical-stage company focused on the development of innovative immunotherapeutics, today announced that the first subject has been dosed in Inimmune’s phase 1/1b First-in-Human clinical trial of INI-2004, Inimmune’s TLR4 agonist product candidate under development […]
Inimmune to present an update on clinical stage vaccine adjuvant and immunotherapy programs at the World Vaccine Congress in Washington DC on April 1st
MISSOULA, Montana, April 1, 2024 Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will present a talk titled ” Alternative uses for adjuvants & cross-over immunotherapy technologies” at the World Vaccine Congress, in Washington […]
Inimmune Corporation and Intrommune therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
MISSOULA, Montana, January 8, 2024NEW YORK, New York, January 8, 2024 Inimmune Corporation (“Inimmune”) and Intrommune Therapeutics, Inc. (“Intrommune”), clinical stage companies focused on the development of innovative immunotherapeutics, today announced an important collaboration. Intrommune is advancing a clinical stage oral mucosal therapy for food allergies in allergic individuals. This revolutionary new immunotherapy will combine […]
Inimmune to present on their novel cancer immunotherapy INI-4001 at the Medinvest Oncology Conference on December 6th, 2023
Missoula, MT, December 1, 2023 – Inimmune, a leading clinical stage biotech company focused on thedevelopment of novel cancer immunotherapies and vaccine adjuvants and delivery systems, announcedtoday that its Chief Operating Officer, Dr. David Burkhart, will give a presentation at the upcomingMedInvest Oncology Conference in Palo Alto California December 5-6th. The event brings togetheroncology investors, […]
Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on our innovative vaccine and adjuvant programs on Wednesday, December 29, 2023 at the World Vaccine Congress (West Coast) in Santa Clara, CA.
Missoula, MT, December 28, 2023 – Inimmune, a leading clinical stage biotech company focused on thedevelopment of novel vaccines and immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at World Vaccine Congress (West Coast). Innovative vaccine adjuvants and delivery technologies have demonstrated great progress for […]
Inimmune Collaborates with Boston Children’s Hospital to Develop Novel Adjuvants
MISSOULA, Mont., Oct. 24, 2023 /PRNewswire/ — Inimmune Corporation, a clinical-stage biotechnology company focused on creating and developing innovative immunotherapeutics, announced that it has entered a research collaboration with Boston Children’s Hospital (BCH) to develop novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby […]
UM and Inimmune Receive $12.3 M NIH Contract to Advance New Adjuvant for Vaccines Targeting Bacterial and Fungal Infections
Contact: Jay Evans, research professor, UM Center for Translational Medicine director, 406-381-0573, jay.evans@umontana.edu. UM Leads $12.3M Contract to Advance TB VaccineUM News Service MISSOULA – The National Institutes of Health recently awarded a $12.3 million contractto the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosisvaccine. Adjuvants are substances that […]
Inimmune announces collaboration with UChicago’s Pritzker School of Molecular Engineering (PME) professor Aaron Esser-Kahn to develop novel vaccine adjuvants
Missoula, MT, October 10, 2023 – With a new NIAID contract, Pritzker Molecular Engineering Prof. Aaron Esser-Kahn will work with UChicago faculty and biotech company Inimmune Inc. to develop a flu vaccine that has fewer side effects for vulnerable populations. READ FULL ARTICLE HERE About Inimmune Corporation Inimmune Corp. (Missoula, MT) is a privately held […]
Inimmune’s Chief Scientific and Strategy Officer, Dr. Jay Evans, will participate in BioJapan and provide a company update on clinical programs on Friday, October 13 in Yokohama, Japan
Missoula, MT, October 10, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at BioJapan (https://jcd-expo.jp/en/). New immunotherapy drugs and vaccine technologies have shown great promise in the treatment of allergy, […]
Inimmune to Present on Novel Adjuvants at the 17th Vaccine Congress on September 26th, 2023
Missoula, MT, September 21, 2023 – Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Operating Officer, Dr. David Burkhart, will give a plenary presentation at the upcoming 17th Vaccine Congress in Glasgow, Scotland September 24-27th. The event brings together […]
Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6.
Inimmune CSO Jay Evans to present an update on clinical stage programs at the International Precision Vaccine Conference in Rome, Italy on October 5-6. Missoula, MT, September 25, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy […]
